Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSatellos Bioscience Inc.

Satellos Bioscience Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.0 CAD 0.00(0%)
Last update at 2026-11-04T14:33:00Z
VOLUME
300
Market Cap
218.73M

Momentum Score

…

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.00
Low
9.00
High
52 Week Price Range
6.24
Low
18.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Satellos Bioscience Inc. (MSCL.TO) is limited, and its core operations, product pipeline and financial condition are not well-documented in accessible filings. For small-cap biotechnology companies, long-term growth drivers typically include clinical or product development milestones, regulatory approvals, licensing agreements and successful capital raises, which investors should monitor. Any future disclosure of development progress or commercial partnerships could support reassessment of the company's prospects.
The primary investment risks include early-stage or unproven operations, high financing and dilution risk, regulatory and clinical development failure, execution risk and low liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-1.51M
Debt / Equity
-
ROE
-66.37%
Net Debt
-9.79M
ROCE
-97.07%
Diluted EPS TTM
-2.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -25.13M -28.10M -15.89M -11.32M -15.51M
Net income -25.31M -28.10M -15.89M -11.32M -15.51M
Selling general administrative 7.44M 8.21M 6.06M 3.96M 1.44M
Gross profit -0.01M -0.02M -8.82M -3.73M -0.12M
Reconciled depreciation 0.00M - - - -
Ebit -26.92M -28.10M -14.13M -8.37M -4.74M
Ebitda -26.92M -28.08M -14.12M -8.03M -4.57M
Depreciation and amortization 0.01M 0.02M 0.01M 0.34M 0.17M
Operating income -26.92M -27.81M -15.46M -8.43M -4.74M
Other operating expenses 26.92M -27.81M 15.46M 8.43M 4.70M
Interest expense - - 0.18M - 0.99M
Tax provision 0.17M 0.00M - - -
Interest income 1.36M 2.67M - - -
Net interest income 1.36M - - - -
Income tax expense 0.18M - 0.18M 0.01M 0.94M
Total revenue 0.00M 0.00M - - -
Total operating expenses 26.92M 27.79M 15.46M 8.43M 4.70M
Cost of revenue 0.01M 0.02M 8.82M 3.73M 0.12M
Total other income expense net 1.79M -0.29M -1.58M -2.95M -9.83M
Net income from continuing ops -24.87M - - - -
Net income applicable to common shares - -20.44M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 31.83M 50.75M 44.30M 6.20M 12.59M
Intangible assets - 0.00M 3.92M 3.92M 7.14M
Other current assets 3.80M 0.00M 0.73M 0.31M 0.57M
Total liab 4.10M 3.58M 3.62M 2.83M 2.10M
Total stockholder equity 27.73M 47.16M 40.67M 3.37M 10.48M
Other current liab 4.10M - 2.58M 1.36M 0.98M
Common stock 85.67M 78.13M 61.92M 30.21M 28.32M
Capital stock 85.83M - - - -
Retained earnings -81.82M -37.13M -47.50M -31.61M -20.29M
Good will - - - -0.00M -
Other assets - - - -0.00M -
Cash 9.79M 8.47M 22.07M 1.92M 4.87M
Cash and equivalents - 40.07M - - -
Total current liabilities 4.10M 3.58M 3.62M 2.83M 2.10M
Net debt -9.79M - -22.07M -1.92M -4.87M
Short term debt - 0.00M - - -
Other stockholder equity 10.15M -1.54M 26.27M 4.78M 2.46M
Property plant equipment - 0.00M - - -
Total current assets 31.83M 50.74M 40.32M 2.23M 5.44M
Long term investments 0.00M - - - -
Short term investments 17.87M - 17.52M - -
Net receivables 0.37M - 0.58M 0.26M 0.53M
Inventory - - -0.58M -0.26M -0.53M
Accounts payable 1.77M - 1.04M 1.47M 1.13M
Accumulated other comprehensive income 13.73M - -0.01M -0.01M -0.00M
Non current assets total 0.00M - 3.98M 3.97M 7.14M
Long term debt total - 0.00M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -9.41M - - - -
Total cashflows from investing activities -9.58M 6.34M - - -
Total cash from financing activities 2.28M 53.48M 51.03M 2.77M 7.45M
Net income -25.31M -28.10M -15.89M -11.32M -15.51M
Change in cash -32.20M 35.59M 20.14M -2.95M 4.15M
Begin period cash flow 41.99M 22.07M 1.92M 4.87M 0.72M
End period cash flow 9.79M 57.66M 22.07M 1.92M 4.87M
Total cash from operating activities -24.01M -24.98M -14.50M -5.78M -5.03M
Issuance of capital stock 0.00M - - - -
Depreciation 0.01M 0.02M 0.01M 0.34M 0.17M
Other cashflows from investing activities - 31.77M - - -
Change to account receivables 0.07M -0.04M - 0.00M 0.04M
Sale purchase of stock - 38.90M - - -
Other cashflows from financing activities - 10.68M 0.60M 2.77M 7.26M
Capital expenditures 0.01M 0.01M 0.02M 0.00M 0.01M
Change in working capital -1.50M -1.02M 0.37M 0.99M -0.49M
Stock based compensation 3.23M 2.11M 2.17M 1.44M 0.97M
Other non cash items 2.80M 2.02M -0.36M -0.14M 9.84M
Free cash flow -24.02M -24.98M -14.52M -5.79M -5.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 6.47
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 20.27
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 -6.36
SVA
Sernova Corp		 -0.01
4.35%		 0.11 - - 65.86 24.15 -11.27

Profile*

Satellos Bioscience Inc.

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Royal Bank Plaza, Toronto, ON, Canada, M5J 2J1

647-660-1780

https://satellos.com

18

Name Title Year Born
Mr. Francis Gleeson B.B.A. M.B.A Co-Founder, CEO, President & Director 1955
Ms. Elizabeth Williams C.A., CPA CFO & Corporate Secretary 1978
Dr. Philip Lambert M.A., Ph.D. Chief Scientific Officer 1969
Mr. William Wasyl Jarosz Executive Director 1956
Mr. Warren Whitehead C.M.A., CPA Head of Corporate Strategy 1952
Dr. Michael Cross M.B.A., Ph.D. Chief Business Officer 1965
Dr. Michael A. Rudnicki Ph.D. Co-Founder & Chief Discovery Officer 1962
Mr. J. Robert Hall CFA Senior Vice President of Finance & Administration NA
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA Strategic Advisor 1960
Ms. Desiree Chan Chief of Staff NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…